moxifloxacin has been researched along with uk 453,061 in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (uk 453,061) | Trials (uk 453,061) | Recent Studies (post-2010) (uk 453,061) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 36 | 14 | 25 |
| Protein | Taxonomy | moxifloxacin (IC50) | uk 453,061 (IC50) |
|---|---|---|---|
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1665 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ndongo, MN; O'Gorman, M; Tawadrous, M; Vourvahis, M; Wang, R | 1 |
1 trial(s) available for moxifloxacin and uk 453,061
| Article | Year |
|---|---|
No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Aza Compounds; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Heart; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Nitriles; Placebos; Pyrazoles; Quinolines; Reverse Transcriptase Inhibitors | 2012 |